BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24117400)

  • 1. Structural basis of the promiscuous inhibitor susceptibility of Escherichia coli LpxC.
    Lee CJ; Liang X; Gopalaswamy R; Najeeb J; Ark ED; Toone EJ; Zhou P
    ACS Chem Biol; 2014 Jan; 9(1):237-46. PubMed ID: 24117400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of LpxC from Pseudomonas aeruginosa complexed with the potent BB-78485 inhibitor.
    Mochalkin I; Knafels JD; Lightle S
    Protein Sci; 2008 Mar; 17(3):450-7. PubMed ID: 18287278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
    Zhou P; Hong J
    Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
    Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
    Cole KE; Gattis SG; Angell HD; Fierke CA; Christianson DW
    Biochemistry; 2011 Jan; 50(2):258-65. PubMed ID: 21171638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design.
    Lee CJ; Liang X; Chen X; Zeng D; Joo SH; Chung HS; Barb AW; Swanson SM; Nicholas RA; Li Y; Toone EJ; Raetz CR; Zhou P
    Chem Biol; 2011 Jan; 18(1):38-47. PubMed ID: 21167751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of Escherichia coli UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase by Fe2+ yields a more efficient enzyme with altered ligand affinity.
    Hernick M; Gattis SG; Penner-Hahn JE; Fierke CA
    Biochemistry; 2010 Mar; 49(10):2246-55. PubMed ID: 20136146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
    Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
    J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
    Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
    Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activities and characterization of novel inhibitors of LpxC.
    Clements JM; Coignard F; Johnson I; Chandler S; Palan S; Waller A; Wijkmans J; Hunter MG
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1793-9. PubMed ID: 12019092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors.
    Liang X; Lee CJ; Zhao J; Toone EJ; Zhou P
    J Med Chem; 2013 Sep; 56(17):6954-6966. PubMed ID: 23914798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold.
    Liang X; Lee CJ; Chen X; Chung HS; Zeng D; Raetz CR; Li Y; Zhou P; Toone EJ
    Bioorg Med Chem; 2011 Jan; 19(2):852-60. PubMed ID: 21194954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Para-(benzoyl)-phenylalanine as a potential inhibitor against LpxC of Leptospira spp.: homology modeling, docking, and molecular dynamics study.
    Pradhan D; Priyadarshini V; Munikumar M; Swargam S; Umamaheswari A; Bitla A
    J Biomol Struct Dyn; 2014; 32(2):171-85. PubMed ID: 23383626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common and varied molecular responses of Escherichia coli to five different inhibitors of the lipopolysaccharide biosynthetic enzyme LpxC.
    Möller AM; Vázquez-Hernández M; Kutscher B; Brysch R; Brückner S; Marino EC; Kleetz J; Senges CHR; Schäkermann S; Bandow JE; Narberhaus F
    J Biol Chem; 2024 Apr; 300(4):107143. PubMed ID: 38458396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
    Zhang J; Zhang L; Li X; Xu W
    Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
    Gao N; McLeod SM; Hajec L; Olivier NB; Lahiri SD; Bryan Prince D; Thresher J; Ross PL; Whiteaker JD; Doig P; Li AH; Hill PJ; Cornebise M; Reck F; Hale MR
    Protein Expr Purif; 2014 Dec; 104():57-64. PubMed ID: 25240855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532.
    Ushiyama F; Takashima H; Matsuda Y; Ogata Y; Sasamoto N; Kurimoto-Tsuruta R; Ueki K; Tanaka-Yamamoto N; Endo M; Mima M; Fujita K; Takata I; Tsuji S; Yamashita H; Okumura H; Otake K; Sugiyama H
    Bioorg Med Chem; 2021 Jan; 30():115964. PubMed ID: 33385955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
    Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
    Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
    Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
    Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.